Brown Capital Management Has Trimmed Quidel (QDEL) Position By $5.42 Million; Cytokinetics (CYTK) SI Decreased By 7.4%

April 17, 2018 - By Nellie Frank

Cytokinetics, Incorporated (NASDAQ:CYTK) Logo

Brown Capital Management Llc decreased Quidel Corp (QDEL) stake by 2.2% reported in 2017Q4 SEC filing. Brown Capital Management Llc sold 125,964 shares as Quidel Corp (QDEL)’s stock rose 13.06%. The Brown Capital Management Llc holds 5.60M shares with $242.75 million value, down from 5.73 million last quarter. Quidel Corp now has $2.09 billion valuation. The stock decreased 0.23% or $0.13 during the last trading session, reaching $56.09. About 130,246 shares traded. Quidel Corporation (NASDAQ:QDEL) has risen 128.16% since April 17, 2017 and is uptrending. It has outperformed by 116.61% the S&P500.

Cytokinetics Incorporated (NASDAQ:CYTK) had a decrease of 7.4% in short interest. CYTK’s SI was 3.03M shares in April as released by FINRA. Its down 7.4% from 3.28 million shares previously. With 532,600 avg volume, 6 days are for Cytokinetics Incorporated (NASDAQ:CYTK)’s short sellers to cover CYTK’s short positions. The SI to Cytokinetics Incorporated’s float is 6.56%. The stock increased 3.23% or $0.25 during the last trading session, reaching $8. About 100,522 shares traded. Cytokinetics, Incorporated (NASDAQ:CYTK) has declined 40.55% since April 17, 2017 and is downtrending. It has underperformed by 52.10% the S&P500.

Among 12 analysts covering Cytokinetics (NASDAQ:CYTK), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Cytokinetics had 23 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Buy” rating given on Friday, September 15 by Needham. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, November 21 report. Needham maintained the stock with “Buy” rating in Wednesday, July 27 report. The firm earned “Neutral” rating on Wednesday, November 22 by Cantor Fitzgerald. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Buy” rating by Morgan Stanley on Wednesday, November 22. The company was maintained on Monday, November 9 by Roth Capital. As per Friday, December 16, the company rating was initiated by Cantor Fitzgerald. FBR Capital maintained the stock with “Outperform” rating in Tuesday, November 10 report. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, February 21. The rating was maintained by MLV on Friday, July 24 with “Buy”.

Since January 16, 2018, it had 0 buys, and 2 selling transactions for $54,471 activity. On Tuesday, January 16 McDowell Caryn Gordon sold $24,381 worth of Cytokinetics, Incorporated (NASDAQ:CYTK) or 2,709 shares. 4,000 shares valued at $30,090 were sold by Blum Robert I on Thursday, April 5.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $432.07 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

Investors sentiment decreased to 1.11 in Q4 2017. Its down 0.28, from 1.39 in 2017Q3. It worsened, as 15 investors sold Cytokinetics, Incorporated shares while 39 reduced holdings. 24 funds opened positions while 36 raised stakes. 38.16 million shares or 2.44% less from 39.12 million shares in 2017Q3 were reported. Schwab Charles Invest Management accumulated 245,793 shares. Arizona State Retirement Sys owns 0.01% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 85,134 shares. Bvf Il holds 5.62% in Cytokinetics, Incorporated (NASDAQ:CYTK) or 5.72M shares. Comerica Bancorp has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK). Vanguard Gp invested 0% of its portfolio in Cytokinetics, Incorporated (NASDAQ:CYTK). Wasatch Incorporated reported 0.18% in Cytokinetics, Incorporated (NASDAQ:CYTK). Hall Laurie J Trustee reported 270 shares. Deutsche Bank Ag holds 0% or 175,832 shares. The Australia-based Macquarie Gru has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Voya Inv Mgmt Lc holds 19,190 shares. Keybank Association Oh accumulated 21,765 shares or 0% of the stock. Geode Cap Mgmt Ltd Liability Company accumulated 428,548 shares. Pnc Fincl Services Gp Inc has 5,069 shares for 0% of their portfolio. Essex Investment Management Ltd reported 0.12% stake. Wellington Mngmt Group Ltd Liability Partnership stated it has 2.16M shares.

Among 9 analysts covering Quidel (NASDAQ:QDEL), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quidel had 36 analyst reports since September 2, 2015 according to SRatingsIntel. Canaccord Genuity maintained Quidel Corporation (NASDAQ:QDEL) on Tuesday, January 2 with “Buy” rating. C.L. King upgraded the shares of QDEL in report on Thursday, January 4 to “Buy” rating. Raymond James maintained the shares of QDEL in report on Tuesday, September 19 with “Outperform” rating. The firm has “Buy” rating by CL King given on Thursday, January 4. As per Friday, December 16, the company rating was downgraded by Piper Jaffray. The rating was maintained by Barclays Capital with “Overweight” on Monday, April 2. The firm has “Overweight” rating by Barclays Capital given on Thursday, July 27. The firm has “Overweight” rating given on Thursday, November 2 by Barclays Capital. The stock has “Buy” rating by Craig Hallum on Monday, March 26. The stock of Quidel Corporation (NASDAQ:QDEL) has “Mkt Perform” rating given on Monday, December 14 by Raymond James.

Investors sentiment decreased to 1.17 in 2017 Q4. Its down 0.03, from 1.2 in 2017Q3. It fall, as 18 investors sold QDEL shares while 35 reduced holdings. 27 funds opened positions while 35 raised stakes. 30.94 million shares or 0.83% more from 30.68 million shares in 2017Q3 were reported. Macquarie Group Inc Ltd, Australia-based fund reported 1.13 million shares. Parametric Associates Ltd Liability Corp reported 0% in Quidel Corporation (NASDAQ:QDEL). Moreover, Pnc Fincl Services Gp has 0% invested in Quidel Corporation (NASDAQ:QDEL) for 526 shares. California Pub Employees Retirement holds 0% or 59,799 shares. New York-based Gagnon Secs has invested 0.43% in Quidel Corporation (NASDAQ:QDEL). Bankshares Of America De owns 0% invested in Quidel Corporation (NASDAQ:QDEL) for 89,242 shares. Alliancebernstein Lp invested 0% in Quidel Corporation (NASDAQ:QDEL). Massachusetts-based Acadian Asset Management Limited Liability Company has invested 0% in Quidel Corporation (NASDAQ:QDEL). Axa holds 206,634 shares or 0.04% of its portfolio. Vanguard Grp Incorporated has invested 0% in Quidel Corporation (NASDAQ:QDEL). Aristotle Boston Ltd Liability Co holds 314,402 shares. The New York-based Tiaa Cref Invest Mngmt Llc has invested 0% in Quidel Corporation (NASDAQ:QDEL). Barclays Public Ltd Co holds 6,172 shares. Moreover, Eam Limited Liability has 0.26% invested in Quidel Corporation (NASDAQ:QDEL) for 45,737 shares. Los Angeles & Equity stated it has 10,620 shares.

Since October 27, 2017, it had 0 insider purchases, and 10 insider sales for $15.28 million activity. The insider BRYANT DOUGLAS C sold 36,000 shares worth $1.60M. Bujarski Robert Joseph had sold 110,704 shares worth $4.40M. Another trade for 12,000 shares valued at $582,031 was sold by SCHULER JACK W. Kroll Werner had sold 16,358 shares worth $661,529 on Friday, December 8. STEWARD RANDALL J had sold 36,383 shares worth $1.46M on Tuesday, December 12. BORKAR RATAN S had sold 29,880 shares worth $1.35 million on Wednesday, January 3.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.